A Phase II Study Of ZD1839 (NSC #715055) In Renal Cell Carcinoma Stage IV And Renal Cell Carcinoma Recurrent
- Determine the response rate in patients with progressive stage IV or recurrent renal
cell cancer treated with ZD 1839.
- Determine the median time to objective progression in these patients receiving this
- Determine the toxic effects of this drug in this patient population.
- Determine if epidermal growth factor receptor expression in tumor tissue correlates
with response and survival of these patients.
OUTLINE: This is a multicenter study.
Patients receive oral ZD 1839 daily. Courses repeat every 28 days in the absence of disease
progression or unacceptable toxicity.
Patients are followed every 8 weeks.
PROJECTED ACCRUAL: A total of 21-45 patients will be accrued for this study within 11-23
Primary Purpose: Treatment
Nancy A. Dawson, MD
University of Maryland Greenebaum Cancer Center
United States: Food and Drug Administration
|Marlene & Stewart Greenebaum Cancer Center, University of Maryland||Baltimore, Maryland 21201|
|Veterans Affairs Medical Center - Baltimore||Baltimore, Maryland 21201|